Most Popular
-
1
S. Koreans' happiness rising slowly but surely: presidential panel
-
2
No. of depression patients exceeds 1m in 2022
-
3
Seoul subway fare to rise 12% beginning Saturday
-
4
Races tighten in Seoul as parties battle for Assembly control
-
5
Korean Air to submit new merger plan to ease antitrust concerns
-
6
US calls on China to encourage N. Korea's return to diplomacy
-
7
US House votes to remove Speaker Kevin McCarthy
-
8
6-year-old Uzbek girl found dead in Daegu
-
9
Korea to begin experiment with central bank digital currency
-
10
22 Chinese apprehended after illegal entry attempt
Genexine, Binex to co-develop coronavirus vaccine GX-19
By Lim Jeong-yeoPublished : March 16, 2020 - 15:13
Korean companies Genexine and Binex will jointly develop potential COVID-19 vaccine “GX-19,” in hopes of preventing yearly seasonal flus showing respiratory symptoms, the companies said Monday.
GX-19 will be a DNA vaccine, developed using Genexine’s platform technology and manufactured at Binex’s “good manufacturing practice”-abiding facility.
A DNA vaccine involves a DNA delivery vector fitted with the genetic information of a particular virus, to which the human immune system may safely develop a defense mechanism. Genexine will inject the DNA of the COVID-19 virus in its delivery vector to test it.
US biotech Inovio has similar technology which it is using in COVID-19 vaccine development. In its research efforts, Inovio had been exempted from the US’ Food and Drug Administration’s toxicity test requirement, and was given a grant of up to $9 million from the Coalition for Epidemic Preparedness Innovations.
In an effort to expedite domestic research, Genexine on Friday had declared the formation of a consortium comprising itself, Binex, the International Vaccine Institute, GenNBio, kaist and postech for the development of GX-19.
Genexine and Binex will begin manufacturing clinical samples from March. The consortium expects to turn in a clinical test design to the drug ministry by June.
“Through this co-development of GX-19, we wish to establish the ground on which we may promptly develop vaccine given whatever novel virus’s advent,” said Genexine and Binex officials.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
GX-19 will be a DNA vaccine, developed using Genexine’s platform technology and manufactured at Binex’s “good manufacturing practice”-abiding facility.
A DNA vaccine involves a DNA delivery vector fitted with the genetic information of a particular virus, to which the human immune system may safely develop a defense mechanism. Genexine will inject the DNA of the COVID-19 virus in its delivery vector to test it.
US biotech Inovio has similar technology which it is using in COVID-19 vaccine development. In its research efforts, Inovio had been exempted from the US’ Food and Drug Administration’s toxicity test requirement, and was given a grant of up to $9 million from the Coalition for Epidemic Preparedness Innovations.
In an effort to expedite domestic research, Genexine on Friday had declared the formation of a consortium comprising itself, Binex, the International Vaccine Institute, GenNBio, kaist and postech for the development of GX-19.
Genexine and Binex will begin manufacturing clinical samples from March. The consortium expects to turn in a clinical test design to the drug ministry by June.
“Through this co-development of GX-19, we wish to establish the ground on which we may promptly develop vaccine given whatever novel virus’s advent,” said Genexine and Binex officials.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
More from Headlines
